These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Palermo M; Alves-Rosa F; Rubel C; Fernández GC; Fernández-Alonso G; Alberto F; Rivas M; Isturiz M Clin Exp Immunol; 2000 Jan; 119(1):77-83. PubMed ID: 10606967 [TBL] [Abstract][Full Text] [Related]
5. LPS-primed CD11b Niu S; Paluszynski J; Bian Z; Shi L; Kidder K; Liu Y Sci Rep; 2018 Mar; 8(1):3994. PubMed ID: 29507316 [TBL] [Abstract][Full Text] [Related]
6. Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model. Palermo MS; Alves Rosa MF; Van Rooijen N; Isturiz MA Clin Exp Immunol; 1999 Jun; 116(3):462-7. PubMed ID: 10361235 [TBL] [Abstract][Full Text] [Related]
7. Role of polymorphonuclear leukocytes in the pathophysiology of typical hemolytic uremic syndrome. Exeni RA; Fernández GC; Palermo MS ScientificWorldJournal; 2007 Aug; 7():1155-64. PubMed ID: 17694250 [TBL] [Abstract][Full Text] [Related]
8. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302 [TBL] [Abstract][Full Text] [Related]
9. Change in conformation with reduction of alpha-helix content causes loss of neutrophil binding activity in fully cytotoxic Shiga toxin 1. Brigotti M; Carnicelli D; Arfilli V; Rocchi L; Ricci F; Pagliaro P; Tazzari PL; Vara AG; Amelia M; Manoli F; Monti S J Biol Chem; 2011 Oct; 286(40):34514-21. PubMed ID: 21832076 [TBL] [Abstract][Full Text] [Related]
10. Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome. Gómez SA; Fernández GC; Camerano G; Dran G; Rosa FA; Barrionuevo P; Isturiz MA; Palermo MS Clin Exp Immunol; 2005 Jan; 139(1):65-73. PubMed ID: 15606615 [TBL] [Abstract][Full Text] [Related]
12. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome. Uchida H; Kiyokawa N; Horie H; Fujimoto J; Takeda T Pediatr Res; 1999 Jan; 45(1):133-7. PubMed ID: 9890621 [TBL] [Abstract][Full Text] [Related]
14. Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin. Ikeda M; Ito S; Honda M Pediatr Nephrol; 2004 May; 19(5):485-9. PubMed ID: 15007712 [TBL] [Abstract][Full Text] [Related]
15. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils. Brigotti M; Carnicelli D; Arfilli V; Tamassia N; Borsetti F; Fabbri E; Tazzari PL; Ricci F; Pagliaro P; Spisni E; Cassatella MA J Immunol; 2013 Nov; 191(9):4748-58. PubMed ID: 24068665 [TBL] [Abstract][Full Text] [Related]
16. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697 [TBL] [Abstract][Full Text] [Related]
17. Experimental In Vivo Models of Bacterial Shiga Toxin-Associated Hemolytic Uremic Syndrome. Jeong YJ; Park SK; Yoon SJ; Park YJ; Lee MS J Microbiol Biotechnol; 2018 Sep; 28(9):1413-1425. PubMed ID: 29926707 [TBL] [Abstract][Full Text] [Related]
18. The Antibiotic Polymyxin B Impairs the Interactions between Shiga Toxins and Human Neutrophils. Carnicelli D; Arfilli V; Ricci F; Velati C; Tazzari PL; Brigotti M J Immunol; 2016 Feb; 196(3):1177-85. PubMed ID: 26695372 [TBL] [Abstract][Full Text] [Related]
19. [Activation of innate and specific immune responses in hemolytic uremic syndrome (HUS)-patients]. Palermo MS; Fernandez GC; Ramos MV; Bentancor L; Fernandez Brando R; Dran GI; Isturiz MA Medicina (B Aires); 2006; 66 Suppl 3():16-21. PubMed ID: 17354472 [TBL] [Abstract][Full Text] [Related]
20. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. Locatelli M; Buelli S; Pezzotta A; Corna D; Perico L; Tomasoni S; Rottoli D; Rizzo P; Conti D; Thurman JM; Remuzzi G; Zoja C; Morigi M J Am Soc Nephrol; 2014 Aug; 25(8):1786-98. PubMed ID: 24578132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]